Daniel Dorgan, MD
Critical Care Medicine · Philadelphia, PANPI 1952523185
Payments from drug & device makers
Across 598 payments — averaging $2971.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$1.7M
- Sanofi US Services Inc.$105K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Consulting fees$18,43280%
- Travel & lodging$4,31919%
- Food & beverage$2261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 565 | $1,669,295 |
| Sanofi US Services Inc. | 8 | $104,694 |
| Boehringer Ingelheim International GmbH | 25 | $2,746 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$12,294
How this compares
$1,776,735 in reported general payments places this provider in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 84 | $2,320,706 |
| ZenpepLipase/Protease/Amylase | 11 | $173,153 |
| Dupixent PenDupilumab | 25 | $89,710 |
| Dupixent SyringeDupilumab | 13 | $49,697 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $44,279 |
| CreonLipase/Protease/Amylase | 12 | $41,627 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $25,922 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $17,050 |
| DuleraMometasone/Formoterol | 16 | $5,134 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $3,722 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,343 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $3,210 |
| Ethambutol Hcl | 60 | $2,292 |
| Azithromycin | 121 | $2,272 |
| Rifampin | 20 | $740 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Philadelphia
- David DibardinoPhiladelphia$2.1M
- Mary KreiderPhiladelphia$637K
- Nadine Al-NaamaniPhiladelphia$421K
- Joshua DiamondPhiladelphia$372K
- Jason FritzPhiladelphia$232K
- Kevin MaPhiladelphia$192K
- Harold PalevskyPhiladelphia$192K
- Belinda Rivera-LebronPhiladelphia$161K
- Michael BeersPhiladelphia$160K
- Kerri SmithPhiladelphia$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.